India's Zydus Lifesciences to benefit from Novartis dropping rival ALS drug, says Bernstein
18/09/2026 09:33
BUZZ-India's Zydus Lifesciences to benefit from Novartis dropping rival ALS drug, says Bernstein ** Zydus Lifesciences ZYDU.NS to benefit from Novartis NOVN.S discontinuing its drug for neurodegenerative disorder ALS for failing to meet goals in mid-stage study, according to Bernstein analysts
** ZYDU's candidate Usnoflast's demonstration of clinically meaningful slowing of disease progression in ongoing Phase II clinical trial to be key - Bernstein rated 5 out of 5 stars overall, per LSEG
** Brokerage rates ZYDU "outperform", PT at street-high 1,457.48 rupees, per LSEG-compiled data
** 15 of 29 analysts rate ZYDU "buy" or higher, median PT 1,205 rupees - LSEG-compiled data
** ZYDU up 1.73% at 1,154.7 rupees; YTD, shares up about 26%
(Reporting by Saikeerthi in Bengaluru)
((Saikeerthi@thomsonreuters.com; (+91) 8296756080))
Recent news on Novartis AG
See all newsEurope Research Roundup: Ambu, Intesa Sanpaolo, Solvay
Swiss pharma industry behind in technology and clinical trials, index shows
European shares rise as Democrats take US Congress, Novo Nordisk surges
European shares rise as Democratic sweep lifts clean energy, bank stocks
Europe set to open lower as Democratic sweep fuels AI regulation fears